A Phase 3, Randomized, Double-Blind, Active-Controlled, Confirmatory Study to Compare the Immunogenicity, Efficacy, and Safety of KD-414 Vaccine and Vaxzevria Vaccine in Adults Aged 18 years and Older - Trial PHRR220620-004783
Access comprehensive clinical trial information for PHRR220620-004783 through Pure Global AI's free database. This Phase 3 trial is sponsored by Meiji Seika Pharma Co., Ltd. and is currently Ongoing. The study focuses on COVID-19.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Philippine Health Research Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
PHRR220620-004783
Phase 3
Ongoing
Trial Details
Philippine Health Research Registry • PHRR220620-004783
A Phase 3, Randomized, Double-Blind, Active-Controlled, Confirmatory Study to Compare the Immunogenicity, Efficacy, and Safety of KD-414 Vaccine and Vaxzevria Vaccine in Adults Aged 18 years and Older
Study Focus
Interventional
Sponsor & Location
Meiji Seika Pharma Co., Ltd.
Japan Philippines
Timeline & Enrollment
Phase 3
May 18, 2022
N/A
ICD-10 Classifications
COVID-19, virus identified
COVID-19, virus not identified
Coronavirus infection, unspecified site
Viral infection, unspecified
Rift Valley fever
Data Source
Philippine Health Research Registry
PHRR220620-004783
Non-Device Trial